CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.

摘要: Abstract Background CYP3A5 gene polymorphism rs776746 has been associated with lower tacrolimus dose requirements and bioavailability in both adults children. This variant causes a loss of activity owing to splice site leading truncated inactive enzyme. The aim this study was determine if the is related time reach therapeutic levels renal transplant Methods A prospective performed children receiving as part their immunosuppressive regime. genotype determined by direct sequencing. Tacrolimus trough serum creatinine at 1 week month after transplantation obtained from clinical chart. Results total 42 patients were included; 19 (45.2%) female, 23 (54.8%) received living-donor transplants, 21 expressed CYP3A5*1/*1 or CYP3A5*1/*3. higher expressers (0.13 vs 0.10 mg/kg/d; P  = .011), 4 (0.17 0.09 mg/kg/d; .008). Conclusions significant functional expressers. Only 42.8% such had levels ≥7 ng/mL despite adjustments. Long-term follow up needed address consequences early post-transplantation differences due genotype.